![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
(D/C/F/TAF) in Treatment-experienced, Virologically Suppressed (EMERALD)
and Treatment-naïve (AMBER) Patients: Week 48 Subgroup Analysis by Age
|
|
|
Reported by Jules Levin
9TH INTERNATIONAL WORKSHOP ON HIV AND AGING;
SEPTEMBER 13-14, 2018; NEW YORK CITY, NEW YORK
Karam Mounzer,1,* Peter Shalit,2 Cristina Mussini,3 Christoph D. Spinner,4 Romana Petrovic,5 John Jezorwski,6 Keith Dunn,7 Eric Y. Wong7
1Philadelphia FIGHT, Philadelphia, PA, USA; 2Tribal Med, Seattle, WA, USA; 3University of Modena and Reggio Emilia, Modena, Italy; 4Technische Universität Munchen, Munich, Germany;
5Janssen Research & Development, Beerse, Belgium; 6Janssen Research & Development, LLC, Pennington, NJ, USA; 7Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
![0924181](../images%20/092418/092419-6/0924181.gif)
![0924182](../images%20/092418/092419-6/0924182.gif)
![0924183](../images%20/092418/092419-6/0924183.gif)
![0924184](../images%20/092418/092419-6/0924184.gif)
![0924185](../images%20/092418/092419-6/0924185.gif)
![0924186](../images%20/092418/092419-6/0924186.gif)
![0924187](../images%20/092418/092419-6/0924187.gif)
![0924188](../images%20/092418/092419-6/0924188.gif)
![0924189](../images%20/092418/092419-6/0924189.gif)
![09241810](../images%20/092418/092419-6/09241810.gif)
![09241811](../images%20/092418/092419-6/09241811.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|